At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SD Sandridge Energy Inc.
Pre-Mkt 03-05 04:43:41 EST
18.08
+0.24
+1.35%
High18.14Low17.45Vol384.32K
Open17.65D1 Closing17.84Amplitude3.88%
Mkt Cap664.87MTradable Cap652.41MTotal Shares36.77M
T/O6.88MT/O Rate1.07%Tradable Shares36.08M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

SandRidge Energy Q4 Adj. EPS $0.34 Misses $0.37 Estimate, Sales $39.400M Miss $43.700M Estimate
Benzinga  ·  05:24
SandRidge Energy Q4 Adj. EPS $0.34 Misses $0.37 Estimate, Sales $39.400M Miss $43.700M Estimate
SandRidge posts Q4 net income of USD 21.6 million up USD 4.1 million
Reuters  ·  05:23
SandRidge posts Q4 net income of USD 21.6 million up USD 4.1 million
SandRidge Energy Q4 Adjusted EPS USD 0.34
THOMSON REUTERS  ·  05:22
SandRidge Energy Q4 Adjusted EPS USD 0.34
SandRidge Energy, Inc. Announces Financial and Operating Results for the Quarter and Year Ended December 31, 2025, $0.12 per Share Cash Dividend, and 2026 Guidance
THOMSON REUTERS  ·  05:22
SandRidge Energy, Inc. Announces Financial and Operating Results for the Quarter and Year Ended December 31, 2025, $0.12 per Share Cash Dividend, and 2026 Guidance
SandRidge Energy Inc. Updates Financial Calendar
Reuters  ·  03-03 05:17
SandRidge Energy Inc. Updates Financial Calendar
Celldex presents new data from Phase 2 ColdU, SD Open Label Extension
TIPRANKS  ·  03-02
Celldex presents new data from Phase 2 ColdU, SD Open Label Extension
Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026
GlobeNewswire  ·  03-01
Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026
Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026
GlobeNewswire  ·  02-28
Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026
SD Guthrie's Key Catalysts Appear Priced In -- Market Talk
Dow Jones  ·  02-26
SD Guthrie's Key Catalysts Appear Priced In -- Market Talk
SD Entertainment Sees FY Net Y210.00M
Dow Jones  ·  02-12
SD Entertainment Sees FY Net Y210.00M
Land Sales Set to Lift SD Guthrie's Earnings Outlook -- Market Talk
Dow Jones  ·  01-29
Land Sales Set to Lift SD Guthrie's Earnings Outlook -- Market Talk
Yahagi Construction To Acquire Kaisho
MT Newswires Live  ·  01-23
Yahagi Construction To Acquire Kaisho
SD Guthrie's Key Catalysts Seems Largely Priced In -- Market Talk
Dow Jones  ·  01-22
SD Guthrie's Key Catalysts Seems Largely Priced In -- Market Talk
Create SD's Attributable Profit Rises 12% in Fiscal H1
MT Newswires Live  ·  01-13
Create SD's Attributable Profit Rises 12% in Fiscal H1
Create SD Holdings 1H Net Y7.89B Vs Net Y7.02B
Dow Jones  ·  01-13
Create SD Holdings 1H Net Y7.89B Vs Net Y7.02B
SD Guthrie's Industrial Land Pipeline Lifts Earnings Visibility -- Market Talk
Dow Jones  ·  01-12
SD Guthrie's Industrial Land Pipeline Lifts Earnings Visibility -- Market Talk
Actuate Therapeutics Announces Positive Patient Outcomes from Phase 1 Trial in Difficult-to-Treat Refractory Pediatric Cancers
GlobeNewswire  ·  01-06
Actuate Therapeutics Announces Positive Patient Outcomes from Phase 1 Trial in Difficult-to-Treat Refractory Pediatric Cancers
NovaBridge Presents Positive Givastomig Dose Expansion Data from the Phase 1b Combination Study in Patients with 1L Metastatic Gastric Cancer
GlobeNewswire  ·  01-06
NovaBridge Presents Positive Givastomig Dose Expansion Data from the Phase 1b Combination Study in Patients with 1L Metastatic Gastric Cancer
SD Guthrie's 4Q Net Profit Likely Sequentially Lower -- Market Talk
Dow Jones  ·  01-06
SD Guthrie's 4Q Net Profit Likely Sequentially Lower -- Market Talk
US Market's Undiscovered Gems to Explore This December 2025
Simply Wall St.  ·  2025-12-24
US Market's Undiscovered Gems to Explore This December 2025

Introduction

Company Name.
Sandridge Energy Inc.
Affiliated Markets:
NYSE
Listing Date:
--
Main Business:
SandRidge Energy, Inc. engages in the acquisition, development, and production of oil and natural gas primarily in the United States Mid-Continent. As of December 31, 2022, it had an interest in 1,471 gross producing wells. The company was incorporated in 2006 and is headquartered in Oklahoma City, Oklahoma.
Issue price:
--